Climb Bio, Inc.
CLYMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How CLYM's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
budoprutug | Phase 2 | Primary Membranous Nephropathy | - | - |
Frequently asked questions
What is in Climb Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Climb Bio, Inc.'s (CLYM) pipeline across Phase 2. Its lead program is budoprutug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Climb Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Climb Bio, Inc. (CLYM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CLYM biotech catalysts?→
Add CLYM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Climb Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.